The shortest peptide almost every cell makes, and it is not a message at all. It is the spare chemistry the cell keeps on hand for itself.
Identity
- Class
- Tripeptide (γ-L-glutamyl-L-cysteinylglycine)
- Source
- Synthesized in the cytosol of nearly every cell by glutamate-cysteine ligase and glutathione synthetase
- Receptor
- No hormone receptor; functions as a cofactor and as a substrate for glutathione peroxidases, transferases, and reductases
Key properties
Evidence floorCommunityREF1COMM1Approximate values for the native hormone; engineered analogs are often deliberately larger and far longer-acting. Each figure carries its own provenance tier, and the floor is the weakest of them - the Standard.
Mechanism
Glutathione is kept at millimolar concentrations inside cells, mostly in the reduced form (GSH). Its cysteine thiol donates electrons to peroxides through the glutathione peroxidases, conjugates electrophiles through the glutathione S-transferases, and is restored from the oxidized dimer (GSSG) by glutathione reductase at the expense of NADPH. Two ATP-dependent enzymes build it: glutamate-cysteine ligase, which is rate-limiting, and glutathione synthetase. The unusual γ-glutamyl bond is what keeps ordinary peptidases from cutting it; outside the cell, γ-glutamyl transpeptidase breaks that bond and clears circulating GSH within minutes. That intracellular redox job is settled biochemistry. It is not a secreted signal, and claims that an injected or oral dose reproduces the intracellular pool are a separate, much thinner question.
Reference notes
- GSH is a tripeptide, but it is assembled by enzymes, not cut from a preprohormone, and it is not a hormone.
- The reduced thiol (GSH) and the oxidized dimer (GSSG) are the pair cells use to buffer oxidative stress.
- Circulating glutathione is short-lived because γ-glutamyl transpeptidase degrades it outside the cell.
- The core biochemistry is textbook. Marketing claims for systemic 'detox' or skin lightening from exogenous glutathione are not that biochemistry.
Regulatory status
United States · verified November 2026- Basis
- No approved glutathione drug. Oral forms are sold as dietary supplements. Injectable glutathione remains in Category 1 of the FDA's interim 503A bulk-substances policy (under evaluation; list updated May 2026). The 2022 Pharmacy Compounding Advisory Committee recommended adding it to the 503A list against FDA staff advice; the vote is non-binding and it is not on the 503A list.
Status describes the molecule as a drug substance under US law and is an editorial reading of the public record — approvals, trial registrations, and the FDA 503A bulk-substances list. It is not legal advice and it changes; the date above is the last time this row was checked. Other jurisdictions are noted only where they differ materially.
Common questions
- What is Glutathione (GSH)?
- The cell's main thiol tripeptide — a redox buffer and enzyme cofactor, made enzymatically rather than released as a hormone. Structurally it is Tripeptide (γ-L-glutamyl-L-cysteinylglycine).
- How does GSH work?
- Glutathione is kept at millimolar concentrations inside cells, mostly in the reduced form (GSH). Its cysteine thiol donates electrons to peroxides through the glutathione peroxidases, conjugates electrophiles through the glutathione S-transferases, and is restored from the oxidized dimer (GSSG) by glutathione reductase at the expense of NADPH. Two ATP-dependent enzymes build it: glutamate-cysteine ligase, which is rate-limiting, and glutathione synthetase. The unusual γ-glutamyl bond is what keeps ordinary peptidases from cutting it; outside the cell, γ-glutamyl transpeptidase breaks that bond and clears circulating GSH within minutes. That intracellular redox job is settled biochemistry. It is not a secreted signal, and claims that an injected or oral dose reproduces the intracellular pool are a separate, much thinner question.
- How strong is the evidence for GSH?
- PeptideHormone grades GSH at the "Established" evidence tier — its mechanism and core effects are settled across the peer-reviewed literature. It is catalogued as an endogenous signal the body produces itself, and the tier is an editorial judgment about the public literature that can change as the science does.
- What is the half-life of GSH?
- The reported circulating half-life of GSH is Minutes in plasma (cleared by γ-glutamyl transpeptidase).
- Is GSH FDA-approved?
- No — as of November 2026, GSH is sold outside the approved-drug system as research-use-only material, with no FDA approval for human use. No approved glutathione drug. Oral forms are sold as dietary supplements. Injectable glutathione remains in Category 1 of the FDA's interim 503A bulk-substances policy (under evaluation; list updated May 2026). The 2022 Pharmacy Compounding Advisory Committee recommended adding it to the 503A list against FDA staff advice; the vote is non-binding and it is not on the 503A list. Status is US-centric and can change; check the FDA record for the current position.
Selected literature
Curated peer-reviewed reviews, sourced from PubMed. Selected for relevance, not exhaustive — open any entry on PubMed for the full record and its primary citations.
- 1.Glutathione. · Annual review of biochemistry, 1983 · PMID 6137189
- 2.Glutathione: overview of its protective roles, measurement, and biosynthesis. · Molecular aspects of medicine, 2009 · PMID 18796312
- 3.Glutathione synthesis. · Biochimica et biophysica acta, 2013 · PMID 22995213
External references
GSH in the public knowledge graph — the same entity resolved across the authoritative chemistry and protein databases.